SCHEMBL9923914

SCHEMBL9923914

Cc1ccc2nc(C(=O)O)c(Cl)n2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.51
RAB9A P51151 4/20 0.51
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GABRA1 P14867 2/20 0.43
GABRB2 P47870 2/20 0.43
GABRB1 P18505 2/20 0.43
LMNA P02545 1/20 0.43
ALB P02768 1/20 0.43
CYP3A4 P08684 1/20 0.43
CHRM1 P11229 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA3 P34903 1/20 0.43
ADRA1A P35348 1/20 0.43
OPRK1 P41145 1/20 0.43
HTR2B P41595 1/20 0.43
GABRA2 P47869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923994 0.83 KDM4E (0.54) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL9923912 0.81 RAB9A (0.55) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL3499281 0.78 SLC2A2 (0.48) ALDH1A1
SCHEMBL24242327 0.77 KDM4E (0.42) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL9893259 0.77 USP7 (0.43) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL22519202 0.75 KDM4E (0.46) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL9924041 0.74 ALDH1A1 (0.50) ALDH1A1HPGDGABRB2ALBOPRK1
SCHEMBL28387628 0.74 KDM4E (0.49) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL2216793 0.74 KDM4E (0.46) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL30024555 0.74 KDM4E (0.51) KDM4ERAB9AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885RAB9A 661/4885ALDH1A1 2230/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885RAB9A 661/4885ALDH1A1 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.